New therapies for neuromyelitis optica spectrum disorder

[1]  Young-A. Heo.  Satralizumab: First Approval , 2020, Drugs.

[2]  Chunshui Yu,et al.  Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial , 2020, The Lancet Neurology.

[3]  A. Traboulsee,et al.  Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial , 2020, The Lancet Neurology.

[4]  T. Misu,et al.  Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial , 2020, The Lancet Neurology.

[5]  M. Levy.  Expanding the spectrum of MOG antibody disease , 2020, Multiple sclerosis.

[6]  J. Pelletier,et al.  Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin‐4 Antibody Diseases , 2020 .

[7]  Jacqueline Palace,et al.  Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. , 2019, The New England journal of medicine.

[8]  Gary R Cutter,et al.  Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial , 2019, The Lancet.

[9]  R. Stern,et al.  Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria , 2019, Therapeutic advances in hematology.

[10]  Jacqueline Palace,et al.  Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. , 2019, The New England journal of medicine.

[11]  M. Benatar,et al.  Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis , 2019, Muscle & nerve.

[12]  J. Wetzels,et al.  Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab , 2019, Clinical Pharmacokinetics.

[13]  Fulin Gao,et al.  Effectiveness of rituximab in neuromyelitis optica: a meta-analysis , 2019, BMC Neurology.

[14]  K. Fujihara,et al.  Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations , 2018, Practical Neurology.

[15]  F. Paul,et al.  Racial differences in neuromyelitis optica spectrum disorder , 2018, Neurology.

[16]  F. Paul,et al.  MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. , 2018, Multiple sclerosis and related disorders.

[17]  A. Verkman,et al.  Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica , 2018, Neuropharmacology.

[18]  F. Paul,et al.  Investigational drugs in development to prevent neuromyelitis optica relapses , 2018, Expert opinion on investigational drugs.

[19]  G. L. Masson,et al.  Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. , 2017, The Lancet. Neurology.

[20]  K. Patra,et al.  Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study , 2017, Multiple sclerosis.

[21]  V. Shaygannejad,et al.  Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial , 2017, Journal of Neurology.

[22]  T. Kanda,et al.  Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[23]  V. Damato,et al.  Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. , 2016, JAMA neurology.

[24]  M. Levy,et al.  Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[25]  R. Marignier,et al.  Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)‐6 produced during remission phase , 2016, Clinical and experimental immunology.

[26]  Jeffrey A. Cohen,et al.  Placebo-controlled study in neuromyelitis optica—Ethical and design considerations , 2015, Multiple sclerosis.

[27]  M. Levy.  The ethics of placebo controlled clinical trials in NMO - A balance of risks. , 2015, Multiple sclerosis and related disorders.

[28]  J. Joo,et al.  Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. , 2015, JAMA neurology.

[29]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[30]  H. Hartung,et al.  Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. , 2015, JAMA neurology.

[31]  J. M. Behne,et al.  Challenges and opportunities in designing clinical trials for neuromyelitis optica , 2015, Neurology.

[32]  S. Zamvil,et al.  Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[33]  M. Levy,et al.  Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica , 2014, Neurology: Neuroimmunology & Neuroinflammation.

[34]  S. Kusunoki,et al.  Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica , 2014, Neurology.

[35]  B. Weinshenker,et al.  Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study , 2013, The Lancet Neurology.

[36]  J. Kira,et al.  Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis , 2013, PloS one.

[37]  R. Gold,et al.  Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. , 2013, JAMA neurology.

[38]  A. Traboulsee,et al.  Treatment of Neuromyelitis Optica: Review and Recommendations. , 2012, Multiple sclerosis and related disorders.

[39]  D. Wingerchuk,et al.  Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. , 2012, Archives of neurology.

[40]  Jiwon Oh,et al.  Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System , 2012, Neurology research international.

[41]  T. Yamamura,et al.  Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica , 2011, Proceedings of the National Academy of Sciences.

[42]  M. Mori,et al.  Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6 , 2010, Multiple sclerosis.

[43]  A. Kimura,et al.  IL‐6: Regulator of Treg/Th17 balance , 2010, European journal of immunology.

[44]  V. Lennon,et al.  Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. , 2009, Archives of neurology.

[45]  Aaron E Miller,et al.  Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. , 2008, Archives of neurology.

[46]  B. Weinshenker,et al.  NMO-IgG predicts the outcome of recurrent optic neuritis , 2008, Neurology.

[47]  S. Vukusic,et al.  Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis , 2006, Annals of neurology.

[48]  Simon A. Jones,et al.  Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-61 , 2005, The Journal of Immunology.

[49]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[50]  Hans Lassmann,et al.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. , 2002, Brain : a journal of neurology.

[51]  B. Weinshenker,et al.  Neuromyelitis optica (Devic's syndrome). , 2014, Handbook of clinical neurology.

[52]  M. Rincón,et al.  The effects of IL-6 on CD4 T cell responses. , 2009, Clinical immunology.